CN109394799B - Natural pharmaceutical composition containing ganoderma lucidum extract and preparation method and application thereof - Google Patents
Natural pharmaceutical composition containing ganoderma lucidum extract and preparation method and application thereof Download PDFInfo
- Publication number
- CN109394799B CN109394799B CN201811624807.7A CN201811624807A CN109394799B CN 109394799 B CN109394799 B CN 109394799B CN 201811624807 A CN201811624807 A CN 201811624807A CN 109394799 B CN109394799 B CN 109394799B
- Authority
- CN
- China
- Prior art keywords
- ganoderma lucidum
- extract
- lucidum extract
- composition containing
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000284 extract Substances 0.000 title claims abstract description 54
- 240000008397 Ganoderma lucidum Species 0.000 title claims abstract description 38
- 235000001637 Ganoderma lucidum Nutrition 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 238000000605 extraction Methods 0.000 title claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 8
- 241000143459 Hirsutella Species 0.000 claims abstract description 29
- 239000003814 drug Substances 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 13
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 6
- 241000222336 Ganoderma Species 0.000 claims description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 238000009835 boiling Methods 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 238000002791 soaking Methods 0.000 claims description 10
- 238000011278 co-treatment Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 238000007873 sieving Methods 0.000 claims description 5
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 5
- 238000001291 vacuum drying Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 238000003809 water extraction Methods 0.000 abstract description 2
- 206010028980 Neoplasm Diseases 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 15
- 239000000243 solution Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 238000002054 transplantation Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 4
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 150000003648 triterpenes Chemical class 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- RDMQPKIDHAFXKA-JNORPAGFSA-N Ganoderic Acid Am1 Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC(=O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CC(=O)CC(C)C(O)=O)C)CC(=O)[C@]21C RDMQPKIDHAFXKA-JNORPAGFSA-N 0.000 description 1
- 229930182735 Ganoderic acid Natural products 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 208000017497 prostate disease Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000008575 shengdi Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a natural medicine composition containing ganoderma lucidum supercritical extract, a preparation method and application thereof, wherein the medicine composition comprises ganoderma lucidum extract and hirsutella hepiali Chen et Shen mycelium extract in a weight ratio of 2:1-1: 2. The invention has simple process and low production cost, and utilizes supercritical CO2The extracted ganoderma lucidum is combined with a hot water extraction method to extract hirsutella hepiali mycelia, and the extracts of the two are prepared into a natural medicinal composition according to a certain proportion, so that the natural medicinal composition has an obvious anti-tumor function.
Description
Technical Field
The invention belongs to the field of health-care food, and particularly relates to a natural pharmaceutical composition containing a ganoderma lucidum extract, and a preparation method and application thereof.
Background
Ganoderma lucidum is also known as Rue Cao and Xiancao, has mild nature and sweet taste, and is a precious Chinese herbal medicine which is always regarded as nourishing, body building, body resistance strengthening and body resistance strengthening by Chinese traditional medicine. The ganoderma lucidum is rich in components, including ganoderma lucidum polysaccharide, triterpene and steroid components, nucleoside, protein, trace elements and the like, wherein the ganoderma lucidum triterpene and the steroid components and the ganoderma lucidum polysaccharide are the main active substances and have been the focus of research in recent years. The modern medicine research shows that the ganoderma lucidum triterpenoids have the effects of resisting tumors, protecting the liver, reducing blood sugar, inhibiting angiotensin, resisting oxidation and the like; the ganoderan has effects of resisting tumor and aging, enhancing immunity, scavenging free radicals, and reducing blood sugar; the ganoderic acid has effects of enhancing disease resistance of human body, reducing cholesterol concentration in blood, and preventing prostate diseases. The components have the functions respectively and have the synergistic effect.
The existing market product is only a preparation of a single ganoderma lucidum extract, and a combined preparation which combines a hirsutella hepiali mycelium extract and a ganoderma lucidum extract and is used for better anti-tumor effect is not available.
Disclosure of Invention
The invention aims to solve the technical problem of the current state of the prior art and provides a natural medicinal composition containing a ganoderma lucidum extract and a hirsutella hepiali mycelium extract with an anti-tumor effect.
The purpose of the invention is realized by the following modes:
a natural pharmaceutical composition containing Ganoderma lucidum extract comprises Ganoderma lucidum extract and hirsutella hepiali Chen et Shen mycelium extract at a weight ratio of 2:1-1: 2.
Preferably, the ganoderma lucidum extract and the hirsutella hepiali Chen et Shen mycelium extract are mixed according to the proportion of 2:1-1: 1.
Further preferably, the ganoderma lucidum extract and the hirsutella hepiali Chen et Shen mycelium extract are mixed in a ratio of 2: 1.
The medicine composition and pharmaceutically acceptable auxiliary materials are prepared into an oral preparation. The oral preparation is preferably tablets, capsules, granules and pills.
The preparation method of the natural medicine composition containing the lucid ganoderma extract comprises the following steps:
(1) crushing lucid ganoderma, sieving the crushed lucid ganoderma with a sieve of 10-20 meshes, soaking lucid ganoderma fine powder obtained after crushing in an ethanol solution for 1-2 hours, and carrying out CO treatment on the soaked lucid ganoderma fine powder2Supercritical extraction, wherein the extraction conditions are as follows: the temperature of the extraction kettle is 38-42 ℃, the pressure of the extraction kettle is 30-35 MPa, and the extraction time is 3-4 h, so that the ganoderma lucidum extract is obtained;
(2) adding 20-30 times of water into hirsutella hepiali mycelia, boiling and extracting for 1-2h, soaking for more than 12h under heat preservation, boiling and extracting for 1-2h again, and concentrating to obtain a concentrated solution; vacuum drying the concentrated solution to obtain hirsutella hepiali mycelium extract;
(3) mixing the ganoderma lucidum extract and the hirsutella hepiali mycelium extract according to the weight ratio of 2:1-1: 2.
The hirsutella hepialid Chen et Shen mycelia adopted by the invention are purchased from Hangzhou Zhongzhi kang mushroom biotechnology limited.
The natural medicine composition has obvious effect in preparing anti-tumor medicine.
Compared with the prior art, the invention has the beneficial effects that: the invention has simple process and low production cost, and utilizes supercritical CO2The ganoderma lucidum is extracted, hot water extraction is combined to extract hirsutella hepiali mycelia, and the extracts of the two are prepared into a natural medicinal composition according to a certain proportion, so that the natural medicinal composition has an obvious anti-tumor function.
The invention is further illustrated below by the efficacy of the inhibition of animal transplantable tumors:
1 test Material
1.1 test drugs: the invention (product of example 1, abbreviated as No. 1), (product of example 2, abbreviated as No. 2), (product of example 3, abbreviated as No. 3), Ganoderma lucidum extract group (total Ganoderma lucidum extract, abbreviated as No. 4), and hirsutella hepiali Chen et Shen mycelium group (total hirsutella hepiali Chen et Shen mycelium extract, abbreviated as No. 5).
1.2 animals: ICR mouse, 18-22g, male and female halves, provided by animal laboratories of Chinese university of pharmacy, wherein the feed is pellet feed, and the feeding conditions are as follows: air-conditioned room, temperature 18-24 deg.C, relative humidity 70%.
1.3 Positive drugs: cyclophosphamide (CTX), shengdi pharmaceutical ltd, Jiangsu. Specification: 0.2 g/bottle.
2 main contents of experiment
2.11, 2, 3, 4 and 5 tail vein injections have the inhibiting effect on Heps of mouse transplantation tumor.
2.21, 2, 3, 4 and 5 tail vein injection on the mouse transplantation tumor S180.
3 Experimental methods and procedures
3.11, 2, 3, 4 and 5 tail vein injections have the inhibiting effect on Heps of mouse transplantation tumor.
3.1.1 routes of administration: tail vein injections No. 1, No. 2, No. 3, No. 4, No. 5 (iv)
3.1.2 dosing cycle: heps solid type was inoculated according to the transplantation tumor study, administered 24 hours after inoculation, iv administered once every other day for 4 times total, and dissected mice were sacrificed on day 2 after drug withdrawal.
3.1.3 dose settings 7 groups, respectively:
blank control group (physiological saline)
No. 1: 3mg/kg
No. 2: 3mg/kg
No. 3: 3mg/kg
No. 4: 3mg/kg
No. 5: 3mg/kg
CTX：30mg/kg
3.1.4 dosing volumes: 0.4ml/20g
3.1.5 methods of experiment: 70 mice with the specification are inoculated with Heps solid types according to a transplantation tumor research method, the mice are weighed 24 hours after inoculation and are randomly divided into 7 groups, 10 mice in each group are half male and female, and a blank control group and a CTX group are respectively a negative control group and a positive control group. Administration 24 hours after inoculation, iv administration, once every other day, 4 total administrations, mice weighed on day 2 after drug withdrawal, tumor bearing mice sacrificed and tumor masses were isolated, weighed and the data statistically processed (t-test).
3.1.6 results of the experiment
The results are shown in Table 1, and the results show that the group iv of No. 1 and No. 2 can obviously inhibit the tumor growth effect of Heps (P is less than 0.05, P is less than 0.01) compared with the blank control group, and simultaneously has the effect of reducing the body weight of experimental mice, but has little influence compared with the positive drug CTX group, and the effect is better than that of the group No. 3, No. 4 and No. 5.
Table 11, 2, 3, 4, 5 iv inhibition of Heps in mice transplantable tumors (X ± SD) (n ═ 10)
Note: p < 0.05P < 0.01 in comparison with the blank control group
Inhibition of mouse graft tumor S180 by tail vein injection of No. 3.21, No. 2, No. 3, No. 4 and No. 5
3.2.1 routes of administration: tail vein injection No. 1, No. 2, No. 3, No. 4, No. 5 (iv)
3.2.2 dosing cycle: s180 solid type was inoculated according to the transplanted tumor study, administered 24 hours after inoculation, iv administered once every other day for 4 times total, and dissected mice were sacrificed on day 2 after drug withdrawal.
3.2.3 dose settings: totally set 7 groups, respectively:
blank control group (physiological saline)
No. 1: 3mg/kg
No. 2: 3mg/kg
No. 3: 3mg/kg
No. 4: 3mg/kg
No. 5: 3mg/kg
CTX：30mg/kg
3.2.4 dosing volumes: 0.4ml/20g
3.2.5 Experimental methods: 70 mice with the specification are inoculated with an S180 solid type according to a transplantation tumor research method, the weight of the mice is weighed 24 hours after inoculation, the mice are randomly divided into 7 groups, each group comprises 10 mice, the male and female groups are half, and a blank control group and a CTX group are respectively a negative control group and a positive control group. Administration 24 hours after inoculation, iv administration, once every other day, 4 total administrations, mice weighed on day 2 after drug withdrawal, tumor bearing mice sacrificed and tumor masses were isolated, weighed and the data statistically processed (t-test).
The results of 3.2.6 are shown in Table 4, and the results show that the group IV administration of the group 1 can obviously inhibit the tumor growth effect of S180 (P is less than 0.01) compared with the blank control group, and simultaneously has the effect of reducing the body weight of the experimental mouse, but has little influence compared with the positive drug CTX group, and the effect is obviously superior to the group 2-5.
Table 41, 2, 3 iv inhibition of mouse graft tumor S180 (X ± SD) (n ═ 10)
Note: p < 0.05P < 0.01 in comparison with the blank control group
Therefore, the invention combines the ganoderma lucidum extract and the hirsutella hepiali Chen et Shen mycelium extract for use, the ganoderma lucidum extract and the hirsutella hepiali Chen et Shen mycelium extract are mutually coordinated and interacted, and the advantages of the ganoderma lucidum extract and the hirsutella hepiali Chen et Shen mycelium extract are combined, thereby obviously improving the utilization rate of the composition and enhancing the effect of inhibiting the animal transplantation tumor.
Detailed Description
The invention is further illustrated by the following specific examples:
example 1
(1) Crushing lucid ganoderma, sieving the crushed lucid ganoderma with a sieve of 10-20 meshes, soaking the lucid ganoderma powder obtained after crushing in a 95% ethanol solution for 1 hour, and carrying out CO treatment on the soaked lucid ganoderma powder2Supercritical extraction, wherein the extraction conditions are as follows: the temperature of the extraction kettle is 40 ℃, the extraction time is 3 hours, and the extraction pressure is 30MPa, so that the ganoderma lucidum extract is obtained;
(2) adding 30 times volume of water into hirsutella hepiali mycelia, boiling and extracting for 2h, soaking for 12h, boiling and extracting for 2h, and concentrating to obtain concentrated solution; vacuum drying the concentrated solution to obtain hirsutella hepiali Chen et Shen mycelium extract;
(3) mixing the ganoderma lucidum extract and the hirsutella hepiali mycelium extract according to the weight ratio of 2: 1.
Example 2
(1) Crushing lucid ganoderma, sieving the crushed lucid ganoderma with a sieve of 10-20 meshes, soaking the lucid ganoderma powder obtained after crushing in a 95% ethanol solution for 2 hours, and carrying out CO treatment on the soaked lucid ganoderma fine powder2Supercritical extraction, extractionTaking conditions as follows: the temperature of the extraction kettle is 38 ℃, the pressure of the extraction kettle is 32MPa, and the extraction time is 4 hours, so that the ganoderma lucidum extract is obtained;
(2) adding 20 times of water into hirsutella hepiali mycelia, boiling and extracting for 1h, soaking for 12h, boiling and extracting for 2h, and concentrating to obtain concentrated solution; vacuum drying the concentrated solution to obtain hirsutella hepiali Chen et Shen mycelium extract;
(3) mixing the ganoderma lucidum extract and the hirsutella hepiali mycelium extract according to the weight ratio of 1: 1.
Example 3
(1) Crushing lucid ganoderma, sieving the crushed lucid ganoderma with a sieve of 10-20 meshes, soaking the lucid ganoderma powder obtained after crushing in a 95% ethanol solution for 2 hours, and carrying out CO treatment on the soaked lucid ganoderma powder2Supercritical extraction, wherein the extraction conditions are as follows: extracting at 42 deg.C under 35MPa for 4 hr to obtain Ganoderma extract;
(2) adding 25 times of water into hirsutella hepiali mycelia, boiling and extracting for 2h, soaking for 12h, boiling and extracting for 2h, and concentrating to obtain concentrated solution; vacuum drying the concentrated solution to obtain hirsutella hepiali Chen et Shen mycelium extract;
(3) mixing the ganoderma lucidum extract and the hirsutella hepiali mycelium extract according to the weight ratio of 1: 2.
Claims (4)
1. A natural medicine composition containing ganoderma lucidum extract is characterized in that the medicine composition comprises the following components in percentage by weight
2:1, the preparation method comprises the following steps:
(1) crushing lucid ganoderma, sieving the crushed lucid ganoderma with a sieve of 10-20 meshes, soaking the lucid ganoderma powder obtained after crushing in an ethanol solution for 1-2 hours, and carrying out CO treatment on soaked lucid ganoderma fine powder2Supercritical extraction, wherein the extraction conditions are as follows: the temperature of the extraction kettle is 38-42 ℃, the pressure of the extraction kettle is 30-35 MPa, and the extraction time is 3-4 h, so that the ganoderma lucidum extract is obtained;
(2) adding 20-30 times of water into hirsutella hepiali mycelia, boiling and extracting for 1-2h, soaking for more than 12h under heat preservation, boiling and extracting for 1-2h again, and concentrating to obtain a concentrated solution; vacuum drying the concentrated solution to obtain hirsutella hepiali mycelium extract;
(3) mixing the ganoderma lucidum extract and the hirsutella hepiali mycelium extract according to the weight ratio of 2: 1.
2. The natural pharmaceutical composition containing ganoderma lucidum extract as claimed in claim 1, wherein the pharmaceutical composition is prepared into an oral preparation together with pharmaceutically acceptable excipients.
3. The natural pharmaceutical composition containing ganoderma lucidum extract according to claim 1, wherein the oral preparation is tablet, capsule, granule or pill.
4. Use of the natural pharmaceutical composition containing ganoderma lucidum extract according to claims 1-3 for the preparation of an anti-tumor medicament.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811624807.7A CN109394799B (en) | 2018-12-28 | 2018-12-28 | Natural pharmaceutical composition containing ganoderma lucidum extract and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811624807.7A CN109394799B (en) | 2018-12-28 | 2018-12-28 | Natural pharmaceutical composition containing ganoderma lucidum extract and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109394799A CN109394799A (en) | 2019-03-01 |
| CN109394799B true CN109394799B (en) | 2021-05-28 |
Family
ID=65462353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811624807.7A Active CN109394799B (en) | 2018-12-28 | 2018-12-28 | Natural pharmaceutical composition containing ganoderma lucidum extract and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109394799B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110237107A (en) * | 2019-05-31 | 2019-09-17 | 嘉兴市爵拓科技有限公司 | Preparation method, its composition and its application of a kind of mountain Soviet Union extract |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102379905B (en) * | 2011-06-22 | 2013-07-24 | 南京中科药业有限公司 | Ganoderma lucidum spore oil-containing Chinese medicinal composition with efficient cancer resistance |
| CN108392500A (en) * | 2018-03-30 | 2018-08-14 | 上海市农业科学院 | A method of preparing ganodenic acid |
-
2018
- 2018-12-28 CN CN201811624807.7A patent/CN109394799B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102379905B (en) * | 2011-06-22 | 2013-07-24 | 南京中科药业有限公司 | Ganoderma lucidum spore oil-containing Chinese medicinal composition with efficient cancer resistance |
| CN108392500A (en) * | 2018-03-30 | 2018-08-14 | 上海市农业科学院 | A method of preparing ganodenic acid |
Non-Patent Citations (1)
| Title |
|---|
| 蝙蝠蛾被毛孢菌丝体通过激活TLR2、TLR4和Dectin-1诱导Th1型免疫反应;陈志蓉等;《中国免疫学杂志》;20091020(第10期);895-902 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109394799A (en) | 2019-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6305457B2 (en) | Application of herbal medicine composition to the preparation of health foods and medicines for the relief and prevention treatment of physical fatigue | |
| CN1762236B (en) | Health-caring product capable of increasing human immunity and its preparation method | |
| CN103768534B (en) | A kind of Chinese medicine composition with antitumor activity | |
| CN101703530A (en) | Mixed fungus ultrafine powder and preparation method thereof | |
| CN111035649B (en) | NMN + GLP compound nutritional supplement and preparation method and application thereof | |
| CN101724667A (en) | Technology for extracting dendrobium polysaccharide by applying biology engineering enzyme technology and product thereof and application | |
| CN104306410A (en) | Triterpene-enriched anti-tumor composition and preparation method thereof | |
| CN105395919A (en) | Composition containing black fungus extract and having effect of reducing blood fat and preparation method of composition | |
| CN101380346B (en) | Traditional Chinese composition for treating tumor and production method thereof | |
| JP6389958B2 (en) | Medicinal use of anti-tumor for rutile pentacyclic triterpene saponins | |
| CN107929337A (en) | A kind of preparation method and application of Panax stipuleanatus Tsai et Feng anti-inflammatory active component | |
| CN109394799B (en) | Natural pharmaceutical composition containing ganoderma lucidum extract and preparation method and application thereof | |
| CN106581166A (en) | Anti-fatigue food, health product or pharmaceutical composition | |
| CN106728208A (en) | A kind of ginseng and lucid ganoderma polysaccharide triterpene preparation and preparation method thereof | |
| Arora | Cordyceps sinensis (berk.) sacc.-an entomophagous medicinal fungus-a review | |
| CN104857180B (en) | Composition for resisting fatigue and improving immunity and preparation method and application thereof | |
| CN112076281A (en) | Ganoderma applanatum composition for enhancing immunity and preparation method thereof | |
| CN108578578B (en) | Pharmaceutical composition with blood fat reducing effect and preparation method thereof | |
| CN110663948A (en) | Health product with immunity enhancing effect and preparation method thereof | |
| CN104510857B (en) | A kind of Chinese medicinal effective-part composition for blood fat reducing and preparation thereof | |
| CN107927745B (en) | A Chinese medicinal health food composition, and its preparation method and preparation | |
| CN109758493B (en) | Application of cardamine hirsute and extract thereof in preparation of drugs for preventing or treating arrhythmia | |
| CN104147070B (en) | A kind of pharmaceutical composition and its preparation process of Prophylactic chemotherapy oral inflammation | |
| CN102133383B (en) | Ginger and fingered citron composition, preparation method thereof and application of ginger and fingered citron composition in preparation of attenuated synergistic medicaments in cancer radiotherapy and chemotherapy | |
| TWI654985B (en) | A use of an extract of a formula including a fruit body of antrodia cinnamomea in the manufacture of a medicament for the treatment of hepatitis b |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |